Durvalumab (the anti–PD-L1 antibody) and tremelimumab (the anti–CTLA-4 antibody) can enhance T cells response to the tumor by blocking the immune checkpoint together, thus generating anti-tumor activity. This evidence concerns the gene CD274 and neoplasm.